首页 › 基金 › SILVERARC CAPITAL MANAGEMENT, LLC › AVLN
SILVERARC CAPITAL MANAGEMENT, LLC 对 AVLN 的持仓历史
AVALYN PHARMACEUTICALS INC · 医疗保健
SILVERARC CAPITAL MANAGEMENT, LLC 在 Q3 2026 的 13F 申报中披露持有 AVLN(AVALYN PHARMACEUTICALS INC)378,352 股,市值约 US$10.8M,约占其申报组合的 1.37%,在其申报持仓中市值排名第 22 位。 SILVERARC CAPITAL MANAGEMENT, LLC 最近 2 个申报季度中有 2 个季度披露了 AVLN 持仓,最早可追溯至 Q2 2026。
最后更新: 2026-11-13 · 来源: SEC EDGAR Form 13F-HR
SILVERARC CAPITAL MANAGEMENT, LLC 对 AVLN 的持仓演变
SILVERARC CAPITAL MANAGEMENT, LLC 于 Q2 2026 首次披露 AVLN 持仓:330,487 股(约 US$10.9M)。 在 2 次申报中,SILVERARC CAPITAL MANAGEMENT, LLC 1 次增持、0 次减持、0 次保持不变。 最近一期申报(Q3 2026)显示持股 378,352 股、市值约 US$10.8M,环比增持 47,865 股。。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q2 2026 | 330.49K | $10.88M | 新进 |
| Q3 2026 | 378.35K | $10.78M | 增持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 AVLN 与 13F 数据
AVLN(AVALYN PHARMACEUTICALS INC)属于医疗保健行业。我们追踪的基金中还有 113 只申报持有 AVLN,申报仓位最大的包括:Novo Holdings A/S (US$127.8M), SR ONE CAPITAL MANAGEMENT, LP (US$108.9M), PERCEPTIVE ADVISORS LLC (US$88.1M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 AVLN 的基金
- Novo Holdings A/S 3.88M 股 · $127.84M · Q2 2026
- SR ONE CAPITAL MANAGEMENT, LP 3.31M 股 · $108.92M · Q2 2026
- PERCEPTIVE ADVISORS LLC 2.68M 股 · $88.07M · Q2 2026
- MONTANOVA CAPITAL, LLC 2.50M 股 · $82.40M · Q2 2026
- NVP Associates, LLC 2.27M 股 · $74.68M · Q2 2026
- Catalio Capital Management, LP 1.68M 股 · $55.17M · Q2 2026
- Bellevue Group AG 1.35M 股 · $44.44M · Q2 2026
- Pivotal bioVenture Partners Investment Advisor LLC 966.79K 股 · $31.83M · Q2 2026
- Andera Partners 929.82K 股 · $26.49M · Q3 2026
- BRAIDWELL LP 801.39K 股 · $26.38M · Q2 2026
- TPG GP A, LLC 773.07K 股 · $25.45M · Q2 2026
- Rock Springs Capital Management LP 662.92K 股 · $21.82M · Q2 2026
更多关于 SILVERARC CAPITAL MANAGEMENT, LLC
常见问题
How long has SILVERARC CAPITAL MANAGEMENT, LLC held AVLN?
SILVERARC CAPITAL MANAGEMENT, LLC has disclosed AVLN holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is SILVERARC CAPITAL MANAGEMENT, LLC's current position in AVLN?
As of Q3 2026, SILVERARC CAPITAL MANAGEMENT, LLC holds 378.35K shares of AVLN (AVALYN PHARMACEUTICALS INC), valued at $10.78M, representing 1.37% of its reported portfolio and ranking #22.
Has SILVERARC CAPITAL MANAGEMENT, LLC been buying or selling AVLN?
In the latest 13F filing (Q3 2026), SILVERARC CAPITAL MANAGEMENT, LLC increased its position in AVLN.
Which other funds hold AVLN?
Other major institutional holders of AVLN include Novo Holdings A/S, SR ONE CAPITAL MANAGEMENT, LP, PERCEPTIVE ADVISORS LLC, among 113 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.